XML 27 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Research and development $ 7,251,097 $ 7,621,707
General and administrative 8,114,654 8,756,767
Total operating expenses 15,365,751 16,378,474
Loss from operations (15,365,751) (16,378,474)
Other income, net 343,724 955,003
Net loss $ (15,022,027) $ (15,423,471)
Net loss available to common stockholders per share of common stock, basic $ (1.61) $ (1.83)
Net loss available to common stockholders per share of common stock, diluted $ (1.61) $ (1.83)
Weighted average number of shares used in calculating net loss per share, basic 9,355,710 8,401,047
Weighted average number of shares used in calculating net loss per share, diluted 9,355,710 8,401,047
Other comprehensive income:    
Reclassification adjustment for interest earned on marketable securities included in net loss $ (430,993)
Change in unrealized gain on marketable securities 334,559
Comprehensive loss $ (15,022,027) $ (15,519,905)